###### Postnatal manifestations of germline ablation of *Rar* and *Rxr* genes.

CD: congenital defects, PnVAD: abnormalities present in postnatal vitamin A-deficiency (Wolbach and Howe, 1925); fetal VAD: abnormalities present in vitamin A-deficiency during pregnancy (Wilson et al., 1953). \#: these abnormalities are completely penetrant. *Rara1*, *Rara2*, *Rarb1/3*, *Rarb2/4*, *Rarg1* and *Rarg2* refer to isoform-specific ablations.
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###### Abnormalities of the fetal vitamin A deficiency (VAD) syndrome (Wilson et al., 1953) present in *Rarb*-null mutants (Aβ), *Rxra*-null mutants and in compound *Rara/b*-, *Rara/g*- and *Rarb/g*-null mutants.

(Aα/Aβ, Aα/Aγ and Aβ/Aγ, respectively). \#, this abnormality is completely penetrant. NA, not applicable, as the corresponding structure is normally not found at E14.5, the time around which *Rxra*-null mutants die. From references (Ghyselinck et al., 1997; Lohnes et al., 1994; Kastner et al., 1994). Note that most of the abnormalities seen in *Rara/b*-null mutants occur at similar frequencies in *Rara/b2*-mutants (Mendelsohn et al., 1994).
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###### Abnormalities absent from the fetal vitamin A deficiency (VAD) syndrome are found in *Rara*-, *Rarb*- and *Rarg*-null mutants (Aα, Aβ, Aγ), and in compound *Rara/b*-, *Rara/g*- and *Rarb/g*-null mutants (Aα/Aβ, Aα/Aγ and Aβ/Aγ).

\#: this abnormality is completely penetrant. From references (Ghyselinck et al., 1997; Lohnes et al., 1994; Kastner et al., 1994). Note that most of the abnormalities seen in *Rara/b*-null mutants occur at similar frequencies in *Rara/b2*-mutants (Mendelsohn et al., 1994).
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###### Evidence that RXRα and RAR act synergistically in embryonic development.

Similar congenital defects absent (or very rare) in *Rxra*-null, *Rxra^af1o^*, *Rxra^af2o^*, and *Rara*-, *Rarb*-, *Rarg*-null mutants are observed in compound *Rxra/Rara*-, *Rxra/Rarb*-, and *Rxra/Rarg*-null mutants (Xα/Aα, Xα/Aβ and Xα/Aγ), in compound *Rxra^af2o^/Rara*-, *Rxra^af2o^/Rarb*-, and *Rxra^af2o^/Rarg*-null mutants (Xα*af2o/*Aα, Xα*af2o/*Aβ and Xα*af2o/*Aγ), in compound *Rxra^af1o^/Rara*-, *Rxra^af1o^/Rarb*-, and *Rxra^af1o^/Rarg*-null mutants (Xα*af1o/*Aα, Xα*af1o/*Aβ and Xα*af1o/*Aγ), as well as in compound *Rara/b*-, *Rara/g*- and *Rarb/g*-null mutants (Aα/Aβ, Aα/Aγ and Aβ/Aγ). \*: this abnormality is present in a majority of the mutants. \#: this abnormality is fully penetrant. VAD, these abnormalities belong to the fetal vitamin A deficiency syndrome (Wilson et al., 1953). From references (Kastner et al., 1997a and 1997b; Mascrez et al., 1998; Kastner et al., 1994; Mascrez et al., 2001).
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Introduction
============

Both clinical findings and experimental approaches have revealed that vitamin A (retinol) and its active derivatives (i.e., the retinoids) exert a wide variety of effects on vertebrate embryonic body shaping and organogenesis, tissue homeostasis, cell proliferation, differentiation and apoptosis (reviewed in \[[@r9]; [@r41]; [@r65]; [@r90]; [@r109]\]). Following Hale's initial demonstration that vitamin A-deficiency (VAD) induces congenital ocular malformations \[[@r35]\], Warkany and his collaborators showed that a large array of congenital malformations affecting the ocular, cardiac, respiratory and urogenital systems (collectively referred as to the fetal VAD syndrome) occurred in fetuses from vitamin A-deficient (VAD) rats (reviewed in \[[@r128]\]). It was shown, much later, that retinoic acid (RA) could replace vitamin A during embryogenesis, at least at certain stages and in certain organs \[[@r21]; [@r127]\].

How RA can exert such pleiotropic effects was a long-standing question, which found its solution with the discovery of two classes of RA-binding transcriptional regulators, the retinoic acid receptors (the multiple isoforms of the RARα, β and γ isotypes), and the retinoid X receptors (the multiple isoforms of the RXRα, β and γ isotypes) (reviewed in \[[@r13]; [@r52]\].

The present review focuses on three main questions: (i) are RARs and RXRs involved in the transduction of RA signals *in vivo*? (ii) to what extent do the observations made *in vivo* support the molecular mechanisms deduced from *in vitro* studies? (iii) what are the developmental events controlled by RARs and RXRs? We summarize and discuss in this review the developmental phenotypes induced by mutations that have been introduced at loci encoding RARs and RXRs, and compare them to the phenotypes resulting either from VAD or from administration of pharmacological doses of antagonistic ligands for RARs in vertebrates, placing emphasis on results obtained in mammals.

RARs and RXRs are instrumental to retinoic acid signalling during embryonic development
=======================================================================================

Signalling through RARs is indispensable for embryonic patterning and organogenesis
-----------------------------------------------------------------------------------

*Rara*, *Rarb*, and *Rarg* null mutant mice are viable. They display some aspects of the fetal (and postnatal) VAD syndromes, as well as a few additional congenital malformations ([Table 1](#table-fn1){ref-type="table"}). However, their abnormalities are restricted to a subset of tissues normally expressing these receptors, probably reflecting the existence of functional redundancies between RARs (discussed in \[[@r41]; [@r42]; [@r63]; [@r66]; [@r67]\]). To test this hypothesis, mutants lacking two RAR isotypes (*Rara/b*-, *Rara/g*- and *Rarb/g*-null mutants), or several isoforms belonging to distinct isotypes were generated. For the sake of clarity, only abnormalities displayed by double null mutants lacking a couple of RAR isotypes (all isoforms deleted) are listed in [Table 2](#table-fn2){ref-type="table"} and [Table 3](#table-fn3){ref-type="table"}. Similar abnormalities, albeit often less penetrant, which are displayed by \"isoform-specific\" double null mutants are listed in \[[@r41]\] (mutants lacking RARα1/RARβ2/4, RARα1/RARγ, RARα1α2^+/-^/RARγ and RARβ2/4/RARγ), in \[[@r111]\] (mutants lacking RARα/RARγ1 and RARα/RARγ2), in \[[@r57]\] (mutants lacking RARα1/RARβ), in \[[@r32]\] (mutants lacking RARα/RARβ1/3 and RARβ1/3/RARγ), and in \[[@r34]\] (mutants lacking RARβ2/RARγ2).

*Rara/b*-, *Rara/g*- and *Rarb/g*-null mutants die *in utero* or at birth because of severe developmental defects that altogether include the complete spectrum of malformations belonging to the fetal VAD-induced syndrome reported by Warkany's group 55 years ago \[[@r128]\] ([Table 2](#table-fn2){ref-type="table"}). As with *Rar*-single-null mutants (see [Table 1](#table-fn1){ref-type="table"}), *Rar*-double-null mutants ([Table 3](#table-fn3){ref-type="table"}) also exhibit congenital abnormalities that were not described in Hale's and Warkany's pioneering fetal VAD studies \[[@r35]; [@r128]\], encompassing ageneses of the Harderian glands, skeletal defects of the skull, face, vertebrae, limbs and forebrain \[[@r31]; [@r54]; [@r55]; [@r57]; [@r79]; [@r111]\]. The occurrence of these "non-VAD" defects in *Rar*- single and double-null mutant mice is most probably accounted for by the difficulty to achieve, by dietary deprivation, a state of profound VAD compatible with pregnancy. In fact, almost all these "non-VAD" defects have been subsequently produced in rodent embryos (i) deficient in vitamin A, but supplemented with RA \[[@r21]; [@r126]; [@r127]\]; (ii) deficient in both RBP (retinol-binding protein) and vitamin A \[[@r100]\]; (iii) lacking the retinaldehyde synthesising enzyme RDH10 (retinol dehydrogenase 10) \[[@r105]\]; (iv) lacking the RA synthesising enzymes RALDH2 (retinaldehyde dehydrogenase 2) \[[@r36]; [@r88]; [@r91]; [@r92]; [@r93]; [@r94]; [@r95]; [@r101]\] or RALDH3 \[[@r26]; [@r36]\] or (v) treated with synthetic retinoids possessing panRAR antagonistic activities \[[@r47]; [@r124]; [@r125]\]. In addition, it was recently found that the Matthew-Wood syndrome, which consists of a spectrum of congenital abnormalities also observed in *Rara/b*, *Rara/g* and *Rarb/g*-null mutants, is caused by mutations in the RBP receptor gene, STRA6 \[[@r33]; [@r98]\]. As *STRA6* loss-of-function mutations most probably yield a state of RA insufficiency in embryonic tissues \[[@r45]\], this discovery provides evidence that RAR signalling performs similar functions during embryonic development in mice and humans.

The comparison of the *Rar*-null mutant phenotypes with those of rodents and humans carrying the aforementioned blocks in RA signal transduction, demonstrate that liganded RARs play crucial roles at many distinct stages of the development of numerous organs (\[[@r41]\] and references therein). For example, the severe malformations found in *Rara/g*-null embryos \[[@r125]\] are similar to those of *Aldh1a2* (formerly Raldh2)-null embryos \[[@r92]\], and reflect early roles of RAR signalling in axial rotation, segmentation and closure of the hindbrain, formation of otocysts, pharyngeal arches and forelimb buds, as well as in closure of the primitive gut. RARs are also indispensable for the ontogenesis of (almost) all the anatomical structures that are derived from mesectodermal cells, i.e. the cranial neural crest cells (NCC) that give rise to mesenchymal derivatives (reviewed in \[[@r41]; [@r62]; [@r66]\]). RARs are involved in antero-posterior patterning of the somitic mesoderm and hindbrain neurectoderm \[[@r24]; [@r31]; [@r54]; [@r55]; [@r125]\], notably through controlling expression of homeobox genes \[[@r2]; [@r22]; [@r24]; [@r38]; [@r97]; [@r106]\]. RARs are also involved in the establishment of the antero-posterior axis of the limbs \[[@r23]; [@r55]; [@r67]\]. RARs are required for the development of a large number of eye structures ([Table 2](#table-fn2){ref-type="table"} and [Table 3](#table-fn3){ref-type="table"}) and for histogenesis of the retina \[[@r31]; [@r34]; [@r55]\], cardiomyocyte differentiation \[[@r40]; [@r43]\], as well as for the control of physiological apoptosis in the retina \[[@r34]\], the frontonasal and interdigital mesenchymes \[[@r18]; [@r23]; [@r31]; [@r55]\], the conotruncal segment of the embryonic heart \[[@r32]\] and the embryonic nephric duct \[[@r8]\]. In the embryonic urogenital tract, RARs control epithelial-mesenchymal interactions in the kidney through expression of the receptor tyrosine kinase Ret \[[@r6]; [@r7]; [@r78]\], as well as the formation of the genital ducts and ureters \[[@r7]; [@r8]; [@r31]; [@r79]\]. In the developing respiratory tract, RA-liganded RARs are necessary for the morphogenesis of the nasal cavities and for their communication with the more caudal airways \[[@r26]; [@r31]\] ([Table 2](#table-fn2){ref-type="table"} and [Table 3](#table-fn3){ref-type="table"}). RA-liganded RARs are also required for the partitioning of the primitive foregut into oesophagus and trachea, and regulate lung branching morphogenesis \[[@r16]; [@r20]; [@r60]; [@r87]; [@r122]\], as well as lung alveoli septation \[[@r70]; [@r71]; [@r72]; [@r77]\] ([Table 1](#table-fn1){ref-type="table"}, [Table 2](#table-fn2){ref-type="table"}, and [Table 3](#table-fn3){ref-type="table"}).

Altogether, the developmental abnormalities of *Rar*-null mutant mice faithfully recapitulate those of rodents lacking the RAR ligand either through dietary vitamin A deprivation or genetically-impaired RA synthesis. There are, however, two notable exceptions to this rule which are related to the control, through RA signalling, of (i) the symmetry of somite patterning and (ii) germ cell differentiation in the embryonic ovary. Concerning somitogenesis, it has been firmly established, in several vertebrate species, that RA is instrumental to the generation of bilaterally symmetrical pairs of somites \[[@r27]; [@r46]; [@r108]; [@r120]\]. It was also recently demonstrated that signalling by RA is required for expression of *Stra8* (stimulated by retinoic acid 8) which, in turn, triggers meiosis in the embryonic ovary \[[@r3]; [@r10]; [@r48]\]. However, defects in the symmetry of somite derivatives, such as vertebrae and muscles, or in the histology of the ovaries, were never observed in *Rara/b*-, *Rara/g*- and *Rarb/g*-null mutant mice. As mentioned above, the apparent lack of phenotypic convergence between the animal models lacking RA and those lacking RARs is probably a consequence of the artificial compensation of the functions of the RARs that are missing in the knockout mice by the remaining one.

RARs have been instrumental to the phylogenesis of mesectodermal derivatives
----------------------------------------------------------------------------

In addition to the dramatic craniofacial skeletal deficiencies affecting *Rara/g*-null mutants \[[@r55]\], subtle defects which often alter the shape of a single skeletal piece are observed in several *Rar*-null mice, including: a cartilaginous or osseous connection between the incus middle ear bone and the alisphenoid bone (the pterygoquadrate element), a cartilage separating the trigeminal ganglion from the brain (the pila antotica) and an agenesis of the rostral ethmoturbinate and maxillary sinus ([Table 3](#table-fn3){ref-type="table"}) \[[@r31]; [@r55]; [@r62]\]. The pterygoquadrate element and the pila antotica, which were lost during evolution from reptiles to mammals, represent atavistic features (discussed in \[[@r62]; [@r66]\]). Along the same lines, ethmoturbinate bones and paranasal sinuses (such as the maxillary sinus) are typical mammalian features not present in reptiles \[[@r96]\]. It is thus conceivable that agenesis of these nasal structures in *Rar*-null mutants also mimics an atavistic condition. The presence of atavistic characteristics in *Rar*-null mutants supports the possibility that changes in the temporal or spatial patterns of expression of *Rar* genes has provided a general mechanism for modifying the number and shape of individual cranial skeletal elements during vertebrate evolution. Interestingly, recent teratogenic experiments using RA in excess have led to similar conclusions \[[@r121]\].

The persistent and hyperplastic vitreous body (PHPV) seen in *Rarb*-null mutants is comparable to the pecten oculi, a normal vascular and pigmented projection from the optic disk found in some reptiles, which is thought to function in the nutrition of the retina \[[@r61]\]. The shortening of the ventral retina observed in *Rarb/g*-null mutants might also be interpreted as a modification towards an ancestral condition, since comparative embryology of the retina shows that the ventral retinal field increases in size as one ascends the vertebrate scale from fishes to amphibia, reptiles and mammals \[[@r61]\]. Thus, RARβ and RARγ might have been instrumental in the expansion of the ventral retinal field during vertebrate evolution.

RXRα is the main RXR isotype involved in embryogenesis
------------------------------------------------------

*Rxra*-null mutants all display a hypoplasia of the compact layer of the ventricular myocardium ([Table 2](#table-fn2){ref-type="table"}), which appears to be the main cause of mutant death occurring by cardiac failure around E14.5 \[[@r40]; [@r43]; [@r104]; [@r113]\]. That a similar myocardium defect is observed in VAD and *Rar*-null fetuses \[[@r79]; [@r128]\], suggests that RXRα is involved in the transduction of the RA signal required for myocardial growth. This requirement is unlikely to be cell-autonomous, as over-expressing RXRα in cardiomyocytes by means of trangenesis does not prevent the *Rxra*-null mutation-induced hypoplasia of the ventricular myocardium \[[@r112]\]. Other data further indicate that *Rxra* expression in the epicardium is required for triggering a paracrine signal necessary for myocardial growth \[[@r15]; [@r39]; [@r80]\].

About one third of the *Rxra*-null mutants lack the conotruncal septum, which normally divides the embryonic heart outflow tract (or conotruncus) into the intracardiac portions of the aorta and the pulmonary trunk \[[@r40]\]. Interestingly, deficiencies of this septum represent both a classical VAD defect in rodents and a leading cause of human congenital heart defects, ranging from high interventricular septal defects to double outlet right ventricle (DORV). In *Rxra*-null mutants, the agenesis of the conotruncal septum appears secondary to an enhanced rate of cell death in both the mesenchymal cells of the conotruncal ridges and the parietal conotruncal cardiomyocytes, therefore indicating that RXRα is required for the transduction of the RA signal that controls apoptosis in the conotruncal segment of the embryonic heart \[[@r32]\].

In addition to heart defects, all *Rxra*-null fetuses display a characteristic ocular syndrome characterized by a PHPV, closer eyelid folds, a thickened ventral portion of the corneal stroma, a ventral rotation of the lens, an agenesis of the sclera and a shortening of the ventral retina ([Table 2](#table-fn2){ref-type="table"}) \[[@r40]\]. As similar defects are present in VAD fetuses and in *Rarb/g*-null mutants ([Table 2](#table-fn2){ref-type="table"}) \[[@r31]; [@r128]\], RXRα appears to play an essential role in the transduction of the RA signals required for several ocular morphogenetic processes, notably the formation of the ventral retinal field.

Importantly, the fact that mice lacking both RXRβ and RXRγ (*Rxrb/g*-null mutants) do not display any obvious morphogenetic defects, even when additionally lacking one allele of *Rxra*, clearly indicates that RXRα is functionally the most important RXR during morphogenesis of the embryo proper \[[@r50]\].

The AF-1-containing A/B domain and the ligand-dependent AF-2 of RXRα are differentially involved in development
---------------------------------------------------------------------------------------------------------------

The role played by RXRs as either "active" or "silent" heterodimerization partners in the transcription of target genes, inferred from *in vitro* studies, has been a controversial issue. To determine the transcriptional role of RXRα *in vivo*, mouse mutants were engineered that express truncated RXRα proteins lacking (i) the N-terminal activation function (AF)-1-containing A/B region (*Rxra^af1o^* mutants) \[[@r68]\], (ii) the AF-2 activating domain (AD) core-containing helix 12 located at the C-terminus of the E region (*Rxra^af2o^* mutants) \[[@r67]\] and (iii) both AF-1 and AF-2 (*Rxra^afo^* mutants) \[[@r69]\].

The *Rxra^af2o^* mutants display the myocardium hypoplasia and the ocular syndrome that are hallmarks of the *Rxra*-null phenotype \[[@r40]\], but at low frequency \[[@r67]\]. This may reflect a functional compensation by RXRβ, as (i) the frequency of the myocardium hypoplasia increases from 5% in *Rxra^af2o^* mutants to 50% upon the additional inactivation of *Rxrb* (which, on its own, has no effect) \[[@r131]\], and (ii) the frequency of the ocular syndrome increases from about 15% in *Rxra^af2o^* mutants to 100% upon further inactivation of *Rxrb* \[[@r67]\]. The full penetrance of the *Rxra*-null ocular syndrome observed in *Rxra^af2o^/Rxrb*-null mutants \[[@r67]\], as well as in *Rxra^afo^* mutants \[[@r69]\], supports the view that the AF-2 of RXRα (and thus possibly a RXR agonistic ligand) is indispensable for ocular morphogenesis. On the other hand, the rare or modest penetrance of the myocardium hypoplasia in *Rxra^af2o^* (5%), *Rxra^af2o^/Rxrb*-null (50%) and *Rxra^af2o^/Rxrb/g*-null mutants (50%) suggests that the transcriptional activity of RXRα becomes necessary for myocardial growth only in "unfavourable" genetic backgrounds. Accordingly, we recently found that the heart histology is normal in 80% of *Rxra^afo^* fetuses \[[@r69]\], indicating that a transcriptionally "silent" RXRα can promote myocardial growth.

Involution of the primary vitreous body represents the developmental process which likely requires the highest concentration of RA-liganded retinoid receptors, since both VAD \[[@r128]\], *Rarb* ablation \[[@r31]\], *Rxra* ablation \[[@r40]\], deletion of RXRα AF-2 \[[@r67]\] and deletion of RXRα AF-1 and AF-2 \[[@r69]\] frequently yield a PHPV. Apart from an occasional PHPV, the *Rxra^af1o^* mutants never display any of the *Rxra*-null developmental defects \[[@r68]\]. This near-absence of defects does not reflect a functional compensation by RXRβ or RXRγ, as *Rxra^af1o^/Rxrb*-null and *Rxra^af1o^/Rxrb/g*-null mutants display no other developmental defect than a PHPV. However, the frequency of this PHPV increases from 10% in *Rxra^af1o^* mutants to 100% in *Rxra^af1o^/Rxrb/g*-null mutants \[[@r68]\]. Altogether, these observations indicate that involution of the primary vitreous body requires both RXRα AF-1 and AF-2, while the other RA-dependent ocular morphogenetic events require RXRα AF-2 only, as they normally take place in the absence of the RXRα AF-1-containing A/B domain.

Thus, these data support the view that the activation functions of RXRα are differentially required for eye morphogenesis and that they can be dispensable for heart development. They also indicate that, due to functional redundancy, the role played by each activation function can be revealed only in genetic backgrounds impaired for RA-signalling (or under RA-insufficiency conditions). Assuming that the frequent requirement of RXRα AF-2 for developmental events reflects the binding of an agonistic ligand, this raises the question of the possible existence and nature of a physiological RXR ligand(s) *in vivo*. The fact that 9-cis RA is undetectable in rodent embryos \[[@r37]; [@r76]\] makes it doubtful that this RXR physiological ligand could be 9-cis RA (reviewed in \[[@r129]\]; see also \[[@r134]\]).

The RXRα AF-1-containing A/B domain has a specific function in the involution of the interdigital mesenchyme
------------------------------------------------------------------------------------------------------------

The AF-2 of RXRα appears functionally more important during development than its AF-1, as (i) *Rxra^af2o^/Rxrb/g*-null fetuses all display a large array of congenital defects and die *in utero*, while *Rxra^af1o^/Rxrb/g*-null fetuses display only a few congenital defects and are often viable; and (ii) transcription of a RA-responsive *lacZ* reporter transgene in the mouse requires RXRα AF-2, but not AF-1 \[[@r67]; [@r68]\]. However, the RXRα AF-1-containing A/B region has a unique role in the RA-dependent disappearance of the interdigital mesenchyme.

The first evidence implicating RA in the involution of the interdigital mesenchyme was provided by organ culture experiments using whole limb in a RA-deprived medium \[[@r58]\]. Subsequently, it was shown that mice lacking both alleles of either *Rara* or *Rarg*, as well as mice heterozygous for the *Rxra*-null mutation occasionally exhibit mild forms of interdigital webbing (i.e., soft tissue syndactyly) ([Table 1](#table-fn1){ref-type="table"}) \[[@r31]; [@r40]; [@r54]; [@r56]\]. Surprisingly, this defect was absent in *Rarb*-null mutants, even though *Rarb* is strongly and specifically expressed in the interdigital necrotic zones (INZs) \[[@r31]\]. However, disruption of one (or both) allele(s) of *Rarb* in a *Rarg*-null genetic background consistently yields interdigital webbing \[[@r31]\]. The persistence of the fetal interdigital mesenchyme responsible for digit webbing is caused by a marked decrease in programmed cell death, as well as by an increase of cell proliferation in the mutant INZs \[[@r23]\]. As *Rarb* and *Rarg* are not co-expressed in the INZs, interdigital mesenchyme involution must involve paracrine interactions between this mesenchyme, which expresses *Rarb*, and either the cartilaginous blastema of the digits or the surface epidermis, which both express *Rarg* (discussed in \[[@r23]\]).

The RXRα AF-1-containing A/B region is indispensable for the function of RXRα/RARβ and/or RXRα/RARγ heterodimers involved in interdigital mesenchyme involution, since the majority of *Rxra^af1o^* mutants and all *Rxra^af1o^/Rxrb/g*-null mutants display a soft tissue syndactyly \[[@r68]\]. In contrast, *Rxra^af2o^* and *Rxra^af2o^/Rxrb/g*-null mutants never display this defect \[[@r67]\], indicating a specific requirement of the RXRα AF-1-containing A/B region in the involution of the interdigital mesenchyme. Interestingly, phosphorylation of RXRα at a specific serine residue located in the A domain is necessary for the anti-proliferative response of F9 teratocarcinoma cells to RA \[[@r5]; [@r102]\]. Phosphorylation of the RXRα A domain may therefore play an important function in the cascade of molecular events that, *in vivo*, leads to the normal disappearance of the interdigital mesenchyme.

Retinoic acid signals are transduced by specific RXRα/RAR heterodimers during development
-----------------------------------------------------------------------------------------

Compound mutants, in which a null mutation of a given RAR isotype is associated either with a *Rxra*-null, a *Rxra^af1o^* or a *Rxra^af2o^* mutation, altogether recapitulate the abnormalities exhibited by *Rar*-null mutants ([Table 4](#table-fn4){ref-type="table"}) \[[@r40]; [@r42]; [@r67]; [@r68]\]. This synergism between *Rar* and *Rxra* loss-of-function mutations supports the conclusion that RXRα/RARα, RXRα/RARβ and RXRα/RARγ heterodimers are the functional units transducing RA signals during embryogenesis. Moreover, that *Rxrb/g*-null mutants develop normally indicates that RXRα is functionally the most important RXR isotype during development \[[@r50]\]. This conclusion is further supported by a lack of synergism, during embryogenesis, between *Rara*-, *Rarb*- or *Rarg*-null mutations and *Rxrb*- or *Rxrg*-null mutations \[[@r42]\].

Comparing the severity and penetrance of a given abnormality between various mutants led to the identification of heterodimers preferentially involved in transducing RA signals in a given developmental process. For instance, myocardium hypoplasia is found in none of the *Rxra^af1o^* mutants and in 5% of the *Rxra^af2o^* mutants. It is observed in 45% of the *Rxra^af1o^/Rara*-null and in 80% of the *Rxra^af2o^/Rara*-null mutants, but in none of the *Rxra^af1o^/Rarb*-null or *Rxra^af1o^/Rarg*-null mutants and in only 20% of the *Rxra^af2o^/Rarb*-null or *Rxra^af2o^/Rarg*-null mutants \[[@r67]; [@r68]\]. Together, these genetic data indicate that RXRα/RARα heterodimers are preferentially transducing the RA signal acting on myocardial growth.

Similarly, although all three RARs are expressed in developing ocular structures \[[@r89]\], several lines of evidence indicate the involvement of RXRα/RARβ and RXRα/RARγ but not of RXRα/RARα heterodimers during eye morphogenesis. Firstly, there is a strong synergism between *Rxra*- and *Rarb*- or *Rarg*-null mutations, which is manifested by a marked increase in the severity of the *Rxra*-null ocular defects, whereas no synergism is observed with the *Rara*-null mutation ([Table 4](#table-fn4){ref-type="table"}) \[[@r42]\]. Secondly, there is also a strong synergism between the *Rarb*- or *Rarg*-null mutations and ablation of either the AF-1-containing A/B domain or the AF-2 of RXRα for the generation of ocular defects ([Table 4](#table-fn4){ref-type="table"}) \[[@r67]; [@r68]\]. In fact, apart from the PHPV discussed above, the characteristic *Rxra*-null ocular syndrome is never observed in *Rxra^af1o^* mutants and is found in less than 15% of the *Rxra^af2o^* mutants. On the other hand, this ocular syndrome is observed in 100% of the *Rxra^af1o^/Rarb*-null, *Rxra^af1o^/Rarg*-null, *Rxra^af2o^/Rarb*-null and *Rxra^af2o^/Rarg*-null mutants, while it is absent in all *Rxra^af1o^/Rara*-null and *Rxra^af2o^/Rara*-null mutants \[[@r67]; [@r68]\]. Altogether, these genetic data indicate that RXRα/RARβ and RXRα/RARγ are the heterodimers which are instrumental to ocular morphogenesis.

Pharmacological and somatic mutagenesis approaches provide clues on RAR-controlled mechanisms operating in the head region during development
=============================================================================================================================================

The endoderm of branchial arches is the target of RA action mediated by RARα and/or RARβ
----------------------------------------------------------------------------------------

*Rara/b*-null mutants, analysed at fetal stages of gestation, display the complete set of defects that can be generated in the chick by surgical ablation of post-otic NCC, namely thymus and parathyroid gland ageneses or ectopias, aberrant patterning of cephalic arteries, absence of pulmonary arteries and aorticopulmonary septum (\[[@r31]; [@r62]; [@r79]\]and references therein). These defects are also present in the CATCH22 syndrome, which is an archetype of human neurocristopathy (i.e., congenital malformations of NCC-derived structures). These and other observations led to the proposal that cranial NCC giving rise to mesenchymal derivatives (i.e., the mesectodermal cells) are major targets of RA action (reviewed in \[[@r64]\]).

Unexpectedly, *Rara/b*-null mutants analysed at embryonic stages of gestation display very small caudal branchial arches (BA), but do not show NCC alterations \[[@r24]\]. BA are transient bulges of the embryonic head and neck, partially filled with NCC, and separated from one another by evaginations of the endoderm, the pharyngeal pouches. Caudal BA and pouches give rise to the adult organs affected in the aforementioned NCC ablation experiments. As the BA defects observed in *Rara/b*-null embryos are less severe than those displayed by embryos lacking RALDH2 (i.e., embryos devoid of RA) \[[@r92]\], they do not reflect a complete block in RA signal transduction. To analyse NCC migration, as well as formation of BA and pharyngeal pouches, in a situation where the degree of the block in RA signal transduction could be precisely controlled, a culture system was designed in which wild-type embryos are exposed, at selected times, to the panRAR antagonist BMS493 \[[@r124]\].

Treatment with BMS493, induces a lack of caudal BA and pharyngeal pouches, and slightly disturbs the paths of post-otic NCC migration, without affecting the amount of NCC. Moreover, and most interestingly, this treatment inhibits caudal BA development only during a narrow window of time, which does not correspond to the period of post-otic NCC migration. Thus, contrary to what was expected from the set of abnormalities displayed by *Rara/b*-null fetuses \[[@r24]\], migrating NCC destined for the caudal BA do not represent exclusive primary targets of RA action. On the other hand, BMS493-induced alterations in endodermal expression of "patterning" genes and of genes encoding peptides involved in paracrine signalling pathways indicate that RA signalling (i) is required to specify the pharyngeal endoderm, and (ii) may provide a permissive environment for NCC migration through secretion of specific paracrine factors by the pharyngeal endoderm \[[@r64]; [@r125]\]. These data also raise the possibility that genes responsible for the human CATCH22 syndrome are actually expressed in the endoderm, under the control of RA during the fourth and fifth weeks of gestation.

RARs act on top of a genetic cascade controlling hindbrain segmentation
-----------------------------------------------------------------------

The embryonic hindbrain is transiently divided into segments (rhombomeres), of which seven (R1 to R7) are visible in mammals. Although early and transient, hindbrain segmentation is instrumental to organize adult structures such as cranial nerves. The hindbrain of *Rara/g*-null embryos shows a posterior expansion of R3 and R4 markers, but fails to express *kreisler*, a specific marker of R5 and R6 \[[@r125]\]. In contrast, the neurectodermal territory corresponding to R5 and R6 is markedly enlarged in *Rara/b*-null embryos \[[@r24]\]. Treating embryonic day (E)7.0 wild-type embryos with the panRAR antagonist BMS493 duplicates the abnormal hindbrain phenotype of *Rara/g*-null embryos, while BMS493 administration started at E8.0 results in a *Rara/b*-null-like phenotype \[[@r124]\]. Therefore, the distinct phenotypes in *Rara/b*- and *Rara/g*-null embryos are related to RA actions during different windows of time. At E7.5 (when RA synthesis begins in the embryo) \[[@r92]\], RARγ and RARα transduce a signal required to specify the R5/R6 territory. At E8.0, RARβ and RARα mediate a local increase in RA signalling in the posterior portion of the hindbrain to control the position of the R6 caudal boundary, thus allowing the next caudal rhombomere, R7, to be specified \[[@r64]; [@r106]; [@r124]\].

That the expression domains of several important hindbrain patterning genes are altered in *Rara/b*- and *Rara/g*-null embryos provides evidence that RA acts on top of the genetic hierarchy controlling hindbrain patterning \[[@r125]\]. Moreover, generation of a graded embryonic block in RA signal transduction through varying the concentrations of the panRAR antagonist in the cultures, demonstrates that individual rhombomeres are specified by distinct thresholds of RA signalling, and support the view that RA acts as a posteriorizing signal for the patterning of the embryonic hindbrain (\[[@r25]; [@r106]; [@r125]\]and references therein). Threshold levels of RA signalling can be set up through modulations of the expression levels of RAR or of RA-synthesising and catabolising enzymes (RALDHs and CYP26s, respectively) \[[@r1]; [@r59]; [@r94]; [@r114]; [@r118]\].

Retinoic acid-dependent eye morphogenesis is orchestrated by the neural crest
-----------------------------------------------------------------------------

As mentioned above, *Rarb/g*-, *Rxra/Rarb*- and *Rxra/Rarg*-null mutants, but not *Rxra/Rara*-null mutants, display similar, albeit much more severe ocular defects than *Rxra*-null mutants, indicating that RXRα/RARβ and RXRα/RARγ heterodimers are instrumental to the morphogenesis of eye structures, including the ventral retina ([Table 2](#table-fn2){ref-type="table"}, [Table 3](#table-fn3){ref-type="table"}, and [Table 4](#table-fn4){ref-type="table"}). Both *Rarb* and *Rarg* are expressed in the periocular mesenchyme (POM), but not in the retina \[[@r31]; [@r89]\]. Therefore, RA signalling in the POM (a NCC-derived tissue) may be instrumental to the morphogenesis of the retina (a neuroectoderm-derived tissue). Using a somatic mutagenesis approach (reviewed in \[[@r81]\]), we have recently demonstrated that selective excision of both *Rarb* and *Rarg* genes in POM precursor cells (*Rarb/g^NCC−/−^* mutants) recapitulates the eye defects generated upon germline ablation of the same receptor genes. In POM cells, RXRα/RARβ and RXRα/RARγ heterodimers appear to control the extent of cell-death involved in POM remodelling and the expression of *Foxc1* and *Pitx2* genes \[[@r73]\], which play crucial roles the development of the anterior eye segment in mice and humans \[[@r19]\]. Interestingly, the POM does not express any RA-synthesizing enzymes (RALDHs), and is therefore unable to synthesise RA. Instead, the neural retina, the retinal pigment epithelium and the corneal ectoderm express both RALDH1 and RALDH3 (\[[@r73]\] and references therein). The fact that in mutants lacking both RALDH1 and RALDH3 (i) the activity of a RA-sensitive reporter transgene is abolished in the POM and (ii) the ocular defects that are generated recapitulate those observed in *Rarb/g*-null mutants establishes that these two RA-synthesizing enzymes provide the RA required to activate RXRα/RARβ and RXRα/RARγ heterodimers in the POM. Therefore, in the developing eye, RA acts as a paracrine signal: it is synthesised by epithelial compartments (i.e., the retina, retinal pigment epithelium and corneal ectoderm), but exerts its effect on the mesenchymal compartment (i.e., the POM). Conversely, the mesenchymal compartment appears to respond to the RA signal by synthesising a yet unknown paracrine factor required for the growth of the ventral retina \[[@r73]; [@r75]\].

Conclusions and perspectives
============================

The phenotypic analyses of mutants lacking retinoid receptors have provided compelling evidence that RA is actually the metabolite of vitamin A, which is active during early embryogenesis, organogenesis, as well as postnatally. This conclusion was subsequently strengthened by the demonstration that RA, synthesized by the retinaldehyde dehydrogenases (RALDH1, RALDH2 and RALDH3), acts as an indispensable developmental hormone \[[@r26]; [@r73]; [@r83]; [@r84]; [@r85]; [@r86]; [@r91]; [@r92]; [@r93]; [@r94]; [@r95]; [@r119]\]. Furthermore, the results from genetic and pharmacological studies conducted in the mouse have proven that the molecular mechanisms underlying transduction of the RA signal by retinoid receptors, which were suggested from *in vitro* studies, are actually instrumental to retinoid signalling under physiological conditions. They have also conclusively established that the teratogenic effects resulting from administration of exogenous RA to embryos do not reflect the physiological role of endogenous RA in the corresponding developmental processes (discussed in \[[@r65]\]).

RXRα/RAR heterodimers are clearly the main functional units transducing RA signals during development, and specific heterodimers are involved in given developmental processes (reviewed in \[[@r63]\]). This strongly supports the initial proposal that the pleiotropic effects of RA reflect sophisticated combinatorial mechanisms, through which multiple RXR/RAR heterodimers differentially transduce retinoid signals to selectively control the expression of numerous sets of RA target genes \[[@r52]\]. Secondly, *in vivo*, the RXR partner can be either transcriptionally active (thus acting in synergy with its RAR partner) or inactive within RXR/RAR heterodimers, depending on the developmental event under consideration. Thirdly, the transcriptional activity of RXR is subordinated to ligand binding to the RAR partner *in vivo* \[[@r28]; [@r74]; [@r85]\], as is the case in cultured cells *in vitro* \[[@r137]; [@r102]; [@r103]\], and when RXRα is transcriptionally active, either one or both activation functions (AF-1 and AF-2) can be involved, their activity depending on the nature of the RA-controlled developmental event \[[@r69]; [@r67]; [@r68]\].

The genetic studies summarized in this review have revealed an extensive functional redundancy within the members of each family (RARs or RXRs), although each of these members appears to individually exert at least one specific physiological function. Since the members of each family share a common ancestor \[[@r29]\], such a redundancy is not surprising. However, it raises the question as to whether it is physiologically relevant or artefactually generated when a given receptor is missing, as is the case in cultured F9 cells \[[@r102]; [@r115]; [@r116]\]. In this respect, note that the existence of two fully redundant genes is, in an evolutionary sense, unlikely \[[@r11]; [@r117]\]. It is also noteworthy that the occurrence of a given morphological defect in *Rar* double-null mutants contrasting with its absence in *Rar* single-null mutants should not be taken as a definite proof of a cell-autonomous functional redundancy. Another possible explanation could imply the action of distinct RARs in different tissues, which may independently direct the making of a given structure. Such a possibility may apply to the case of the interdigital soft tissue, which involutes normally in all *Rarb*- and in almost all *Rarg*-null mutants, but persists in all *Rarb/g*-null mutants yielding webbed digits ([Table 1](#table-fn1){ref-type="table"} and [Table 3](#table-fn3){ref-type="table"}). In this instance, a functional cell-autonomous redundancy between RARβ and RARγ is hardly conceivable, as *Rarb* and *Rarg* exhibit non-overlapping expression patterns in the limbs \[[@r31]\].

Importantly, there is much less functional redundancy in RXRα/RAR compound mutants ([Table 2](#table-fn2){ref-type="table"}, [Table 3](#table-fn3){ref-type="table"}, and [Table 4](#table-fn4){ref-type="table"}). As RXRα/RAR heterodimers are the functional transducing units, the easiest way to interpret these observations is to postulate that redundancy occurs only when a single partner of the "physiological heterodimer" is missing \[[@r42]; [@r67]; [@r68]\]. In other words, the activity of the "alternative heterodimer" may still be above the functional threshold level when either the RXR or the RAR partner of the "physiological heterodimer" is missing, but not when both are deleted. According to this interpretation, the selective involvement of a given RAR or RXR could be revealed only under conditions where the functional threshold level is not reached. This would notably account for the observations that the role of the RXRα AF-1 or AF-2 cannot be fully revealed, unless the activity of the "physiological heterodimer" is altered by the additional ablation of either the RAR partner or the redundant RXR isotypes \[[@r67]; [@r68]\]. Thus, any conditions which would lower the activity of RXR/RAR heterodimers (for instance a decreased availability of RA), may reduce or abrogate functional redundancy. As the supplies in vitamin A, the precursor of RA, could be more limiting in wild-life than in the context of an animal facility, the functional redundancies between RAR and RXR may therefore be much less prominent in natural environments.

Quite surprisingly, RXR loss-of-function mutants do not display defects in morphogenesis other than those observed in the fetal VAD syndrome or upon ablation of the RA-synthesizing enzymes. This suggests that RXRs are involved in morphogenesis solely through their heterodimerization with RARs. Accordingly, mice harbouring null mutations for the other nuclear receptors (NRs) dimerizing with RXRs and for which a ligand is known (i.e., PPARα, PPARβ, TRα, TRβ, VDR, LXRα, LXRβ, FXR, PXR, CAR) do not display morphological abnormalities \[[@r30]; [@r44]; [@r51]; [@r99]; [@r158]; [@r107]; [@r110]; [@r123]; [@r130]\], with the exception of PPARγ-null mice \[[@r4]\]. In this latter case, the embryonic heart defect is clearly secondary to a severe placental hypoplasia \[[@r4]\]. Thus, amongst the multiple "hormone-like" signals that RXR/NR heterodimers can integrate, RA appears to be the most crucial, if not the only one involved in morphogenesis of the embryo proper.

The genetic approach summarized in this review has provided valuable insights on the functions of RA receptors during development. However, this strategy has intrinsic limitations, which are mostly due to the introduction of mutations in the germline. First, the effect of a germline mutation may be functionally compensated for during development, thus precluding the appearance of a defect. On the other hand, the mutation can be lethal *in utero* (e.g., the *Rxra* knockout and the RAR compound null mutants), thus preventing analysis of the functions of the gene at postnatal stages. The mutation can also arrest the development of a given organ at an early stage, thus precluding further analysis of the gene functions at a later stage. Moreover, introducing mutations in germline makes it difficult to distinguish cell-autonomous from non-cell autonomous functions of genes belonging to families, such as RARs and RXRs that are involved in pleiotropic signalling pathways. In many instances, these limitations may actually prevent the determination of the function of a given gene product in a defined cell type/tissue and/or at a given time of the life of the animal. This is obviously the case for RARs and RXRs.

To overcome all these limitations, strategies for spatio-temporally-controlled somatic mutagenesis of RARs and RXRs in mice have been designed, which are based on the cell type-specific expression of a tamoxifen-inducible form of the Cre recombinase (called Cre-ER^T^ and Cre-ER^T2^) (reviewed in \[[@r81]; [@r82]\]). The combined use of transgenic mice expressing chimeric tamoxifen-inducible Cre recombinases in specific cell types and of mouse lines harbouring loxP-flanked conditional alleles for RAR and RXR genes will provide invaluable models to elucidate the postnatal functions of retinoid receptors.

AD

:   activating domain

AF

:   activation function

BA

:   branchial arche

CYP

:   cytochrome P450 hydroxylase

DORV

:   double outlet right ventricle

E

:   embryonic day

INZ

:   interdigital necrotic zone

NCC

:   neural crest cells

NR

:   nuclear receptor

PHPV

:   persistent and hyperplastic vitreous body

POM

:   periocular mesenchyme

R1 to R7

:   rhombomeres 1 to 7

RA

:   retinoic acid

RALDH

:   retinaldehyde dehydrogenase

RAR

:   retinoic acid receptor

RBP

:   retinol-binding protein

RDH

:   retinol dehydrogenase

RXR

:   retinoid X receptor

STRA

:   stimulated by retinoic acid

VAD

:   vitamin A-deficiency
